Antibiotice Ia (ATB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Antibiotice Ia (ATB) has a cash flow conversion efficiency ratio of 0.020x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RON18.71 Million ≈ $4.30 Million USD) by net assets (RON930.75 Million ≈ $213.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Antibiotice Ia for the company's overall valuation and market capitalisation.
Antibiotice Ia - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Antibiotice Ia's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Antibiotice Ia (ATB) share price today for real-time trading data and today's change.
Antibiotice Ia Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Antibiotice Ia ranked by their cash flow conversion efficiency. Review free cash flow generation of Antibiotice Ia to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Benli Technology Co. Ltd.
SHE:301065
|
N/A |
|
Regional Management Corp
NYSE:RM
|
0.216x |
|
Drugs Made In America Acquisition Corp. Units
NASDAQ:DMAAU
|
-0.001x |
|
CapMan Oyj B
HE:CAPMAN
|
-0.087x |
|
Inmobiliaria del Sur SA
MC:ISUR
|
-0.025x |
|
Tianjin Hi-Tech Development Co Ltd
SHG:600082
|
0.317x |
|
SNDL INC.
F:VY4
|
0.003x |
|
Super Group Ltd.
JSE:SPG
|
0.109x |
Annual Cash Flow Conversion Efficiency for Antibiotice Ia (2022–2025)
The table below shows the annual cash flow conversion efficiency of Antibiotice Ia from 2022 to 2025. Also see ATB total asset value for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | RON932.07 Million ≈ $214.02 Million |
RON72.44 Million ≈ $16.63 Million |
0.078x | -26.95% |
| 2024-09-30 | RON894.31 Million ≈ $205.35 Million |
RON95.15 Million ≈ $21.85 Million |
0.106x | -26.42% |
| 2023-09-30 | RON846.96 Million ≈ $194.48 Million |
RON122.46 Million ≈ $28.12 Million |
0.145x | -19.82% |
| 2022-09-30 | RON641.43 Million ≈ $147.28 Million |
RON115.66 Million ≈ $26.56 Million |
0.180x | -- |
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system prepar… Read more